Armistice Capital (SGMOQ) discloses 38.9M-share, 9.38% position in Sangamo

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 38,860,819 shares of Sangamo Therapeutics, Inc. common stock, representing 9.38% of the outstanding class as of June 30, 2026. They report shared voting and dispositive power over all of these shares and no sole voting or dispositive power.

The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may be deemed to beneficially own the same securities.

Key Figures

Beneficial ownership: 38,860,819 shares Percent of class: 9.38% Shared voting power: 38,860,819 shares +3 more

6 metrics

Beneficial ownership 38,860,819 shares Common stock beneficially owned by Armistice Capital and Steven Boyd as of June 30, 2026

Percent of class 9.38% Percentage of Sangamo Therapeutics common stock represented by the reported holdings

Shared voting power 38,860,819 shares Shares over which the Reporting Persons have shared power to vote or direct the vote

Shared dispositive power 38,860,819 shares Shares over which the Reporting Persons have shared power to dispose or direct disposition

Sole voting power 0 shares Shares over which the Reporting Persons have sole power to vote or direct the vote

Sole dispositive power 0 shares Shares over which the Reporting Persons have sole power to dispose or direct disposition

Key Terms

beneficially own, investment manager, Investment Management Agreement, exempted company, +1 more

5 terms

beneficially own financial

"Armistice Capital exercises voting and investment power... and thus may be deemed to beneficially own the securities"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

investment manager financial

"Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd."

Investment Management Agreement financial

"pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power"

An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.

exempted company financial

"The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital"

Joint Filing Statement regulatory

"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

How much of Sangamo Therapeutics (SGMOQ) does Armistice Capital beneficially own?

Armistice Capital and Steven Boyd report 38,860,819 shares of Sangamo Therapeutics common stock, representing 9.38% of the outstanding class as of June 30, 2026, with shared voting and dispositive power over all reported shares.

Who directly holds the Sangamo Therapeutics (SGMOQ) shares reported by Armistice Capital?

The 38,860,819 shares are held directly by Armistice Capital Master Fund Ltd.. Armistice Capital, as investment manager under an Investment Management Agreement, exercises voting and investment power over these Sangamo Therapeutics securities on behalf of the Master Fund.

What voting and dispositive powers are reported over SGMOQ shares?

Armistice Capital and Steven Boyd report 0 shares with sole voting or dispositive power and 38,860,819 shares with shared voting and shared dispositive power, corresponding to 9.38% of Sangamo Therapeutics’ common stock as of June 30, 2026.

How is Steven Boyd related to Armistice Capital’s SGMOQ holdings?

Steven Boyd is the managing member of Armistice Capital, LLC. Because Armistice Capital manages Armistice Capital Master Fund Ltd., Boyd may be deemed to beneficially own the 38,860,819 Sangamo shares held by the Master Fund through this role.

Who has the right to receive dividends or sale proceeds from the SGMOQ shares?

The filing states that Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and investment advisory client of Armistice Capital, has the right to receive dividends and sale proceeds from the reported Sangamo Therapeutics securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:26 AM Accepted by SEC EDGAR 08/14/2026 - 10:26 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

SANGAMO THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

800677106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 800677106

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 38,860,819.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 38,860,819.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

38,860,819.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.38 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 800677106

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 38,860,819.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 38,860,819.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

38,860,819.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.38 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SANGAMO THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 501 Canal Blvd., Richmond, California 94804
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP No.: 800677106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 38,860,819
(b)	Percent of class: 9.38%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 38,860,819
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 38,860,819 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	08/14/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	08/14/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd